<DOC>
	<DOCNO>NCT00866879</DOCNO>
	<brief_summary>This study do investigate impact change immunosuppressive medication tacrolimus ( Prograf® ) sirolimus ( Rapamune® ) 6 24 month post transplant . The primary purpose research study evaluate whether use mycophenolate mofetil ( MMF ) /Cellcept® tacrolimus ( TAC ) /Prograf® ( Group 1 ) mycophenolate mofetil ( MMF ) /Cellcept® sirolimus/Rapamune® ( Group 2 ) impact incidence acute cellular rejection post kidney transplant patient . This study examine whether switch tacrolimus sirolimus well preserve long-term kidney function .</brief_summary>
	<brief_title>Randomized Conversion Calcineurin-Inhibitors Renal Allograft Recipients</brief_title>
	<detailed_description>For research study , 6 24 Months post-transplant , plan prospectively randomize 2:1 renal transplant patient either : - Substitute tacrolimus ( TAC ) sirolimus continue mycophenolate mofetil ( MMF ) - Continue tacrolimus ( TAC ) mycophenolate mofetil ( MMF ) A total 400 patient expect screened randomization . We expect randomize 275 renal transplant patient protocol ( 275 donor recruit ) . The following data collect time randomization : Recipient demographic : ( ) age transplantation , ( ii ) sex , ( iii ) race . Clinical history : ( ) cause end-stage renal disease , ( ii ) past medical history . Transplant related information : ( ) donor age , ( ii ) cadaveric versus live kidney transplant , ( iii ) histocompatibility cross match data , ( iv ) viral serology , ( v ) history acute rejection delay graft function , ( vi ) use induction therapy immunosuppressant , ( vii ) use ACEI and/or ARB , ( viii ) level renal allograft function-estimated GFR ( e-GFR ( 12 ) use MDRD formula , proteinuria . Peripheral blood leukocyte obtain renal transplant recipient baseline ( prior randomization ) lymphocytes functional activity characterization lymphocytes subpopulation flow cytometry analysis . Peripheral donor leukocyte ( live donor patient ) also obtain time randomization . These donor leukocyte use stimulator cell study functional activity recipient 's lymphocyte function . The recipient assign continue tacrolimus MMF routinely follow outpatient Comprehensive Transplant Center ( CTC ) monthly lab . In addition lab baseline pre-randomization , 6 , 12 24 Months post-randomization , peripheral blood leukocyte obtain study lymphocytes functional activity characterize lymphocytes subpopulation flow cytometry analysis . Post randomization : The recipient assign switch tacrolimus sirolimus continue MMF routinely follow CTC monthly lab . During period conversion tacrolimus sirolimus , weekly lab obtain monitor renal function bone marrow function . In addition lab baseline pre-randomization , 6 , 12 24 Months post-randomization , peripheral blood leukocyte obtain study lymphocytes functional activity characterize lymphocytes subpopulation flow cytometry analysis . Urine collect assess tubular toxicity evaluate urinary biomarkers . Both group patient follow 2 year post-randomization . In addition monitoring renal allograft function , evaluate incidence acute rejection , patient graft survival , impact CI conversion lipid profile , incidence hypertension , malignancy , opportunistic infection , post-transplant diabetes mellitus ( DM ) . For willing undergo optional kidney biopsy , one perform end second year order evaluate renal allograft pathology renal allograft tissue gene expression profile two group . With peripheral leukocyte obtain baseline prior randomization 6 , 12 24 Months post-randomization , investigate possible modification lymphocytes function lymphocyte subpopulation might occur consequence switch tacrolimus sirolimus . Obtaining renal allograft tissue sample 24 month post randomization potential important ramification help explain mechanisms fibrosis tubular atrophy typically associate CI role CI elimination substitution sirolimus ( SRL ) . All data analyze compare gene expression profile peripheral blood ( Pax gene tube routinely collect different time point part original study ) . Based power analysis , perform 24 month post randomization biopsy 70 % total subject enrol study ( approximately 46 subject tacrolimus/MMF group approximately 93 subject sirolimus/MMF group ) . We plan obtain renal allograft biopsy 24 Months consent additional biopsy . This compare standard care 12 month post-transplant biopsy allow u address effect immunosuppressive modification renal allograft pathology 24 month post randomization . Renal allograft biopsy also store RNA later extend knowledge effect CI free immunosuppression gene expression profile .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>1 . Subjects adults ≥ 18 ≤ 70 year age 2 . Subjects either gender ethnic background 3 . Subjects single organ recipient ( kidney ) 4 . Subjects must able understand protocol provide inform consent . 1 . Subjects endstage renal disease ( ESRD ) secondary primary focal segmental glomerulonephritis ( FSGS ) . 2 . Inability comply study procedures 3 . Inability sign inform consent 4 . Subjects significant active infection 5 . Subjects pregnant nursing female 6 . Subjects history severe hyperlipidemia control statin , patient total cholesterol &gt; 400 mg/dl 7 . Subjects platelet count &lt; 100,000mm3 white blood cell ( WBC ) &lt; 2,000mm3 8 . Subjects severe proteinuria time randomization ( &gt; 2gm/day ) 9 . Subjects 2 episode acute cellular rejection post transplantation exclude study 10 . An estimated GFR &lt; 40 cc/min 11 . A history malignancy posttransplant period ( treat basal cell cancer and/or squamous cell cancer ) 12 . Subjects , , due existence surgical , medical psychiatric condition , current transplant , opinion investigator , precludes enrollment trial 13 . A history albumincreatinine ratio ( ACR ) recent previous 3 month prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Sirolimus</keyword>
	<keyword>Rapamune</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Renal allograft function</keyword>
	<keyword>Lymphocytes function</keyword>
</DOC>